Inhaled antibiotics to treat lung infection (Q38162996)

30 August 2017

title

Inhaled antibiotics to treat lung infection (English)

1 reference

30 August 2017

0 references

1 reference

30 August 2017

1 reference

30 August 2017

publication date

1 September 2013

1 reference

Pharmaceutical patent analyst

30 August 2017

published in

1 reference

30 August 2017

1 reference

30 August 2017

1 reference

30 August 2017

page(s)

647-663

1 reference

Recent advances in the treatment of Pseudomonas aeruginosainfections in cystic fibrosis

30 August 2017

cites work

1 reference

MP-376 (Aeroquin) for chronic Pseudomonas aeruginosa infections

21 January 2018

1 reference

Inhaled colistin for lower respiratory tract infections.

21 January 2018

1 reference

New developments in inhaled antibiotics for the treatment of Pseudomonas aeruginosa

21 January 2018

1 reference

Development of the First Inhaled Antibiotic for the Treatment of Cystic Fibrosis

21 January 2018

1 reference

Aerosolized antibiotics: the past, present and future, with a special emphasis on inhaled colistin

21 January 2018

1 reference

Trends in the use of routine therapies in cystic fibrosis: 1995-2005.

21 January 2018

1 reference

Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis

21 January 2018

1 reference

A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis

21 January 2018

1 reference

Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis

21 January 2018

1 reference

Delivery of antibiotics to the respiratory tract: an update

21 January 2018

1 reference

Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent?

21 January 2018

1 reference

Regulatory aspects of Phase 3 endpoints for new inhaled antibiotics for cystic fibrosis patients with chronic Pseudomonas aeruginosa infections

21 January 2018

1 reference

Treatment of lung infection in patients with cystic fibrosis: current and future strategies

21 January 2018

1 reference

Biofilms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials

21 January 2018

1 reference

Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections

21 January 2018

1 reference

Aerosolized antibiotics for non-cystic fibrosis bronchiectasis

21 January 2018

1 reference

Antimicrobial therapy for bronchiectasis

21 January 2018

1 reference

Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications

21 January 2018

1 reference

Aerosolized antibiotics in the intensive care unit

21 January 2018

1 reference

Ciprofloxacin DPI in non-cystic fibrosis bronchiectasis: a Phase II randomized study

21 January 2018

1 reference

Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution

21 January 2018

1 reference

Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection

21 January 2018

1 reference

Liposomal formulations for inhalation

21 January 2018

1 reference

Current dilemmas in antimicrobial therapy in cystic fibrosis.

21 January 2018

1 reference

Liposomes in pulmonary applications: physicochemical considerations, pulmonary distribution and antioxidant delivery

21 January 2018

1 reference

Update in cystic fibrosis 2012.

21 January 2018

1 reference

Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection

21 January 2018

1 reference

Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis

21 January 2018

1 reference

Inhaled aztreonam lysine for cystic fibrosis pulmonary disease-related outcomes

21 January 2018

1 reference

Aztreonam lysine for inhalation: new formulation of an old antibiotic

21 January 2018

1 reference

Aztreonam (for inhalation solution) for the treatment of chronic lung infections in patients with cystic fibrosis: an evidence-based review

21 January 2018

1 reference

Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects

21 January 2018

1 reference

Inhaled antibiotics for lower respiratory tract infections: focus on ciprofloxacin

21 January 2018

1 reference

Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study

21 January 2018

1 reference

Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia

21 January 2018

1 reference

Inhaled anti-infective agents: emphasis on colistin

21 January 2018

1 reference

The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.4155/PPA.13.47

1 reference

30 August 2017

1 reference